Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 13, 2020
Reporting Period: Single event date (August 13, 2020)
The filing reports a specific corporate event regarding intellectual property rather than a standard financial reporting period. The Company is an emerging growth company focused on developing therapeutic candidates, including XPro1595.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing is limited to reporting a specific event under Item 8.01 (Other Events).
Material Changes
Intellectual Property Grant:
- The European Patent Office (EPO) granted EP Pat. No. 2,892,547.
- Title: "A DOMINANT NEGATIVE TNF-ALPHA INHIBITOR FOR USE IN TREATING NEUROLOGICAL DISORDERS OF THE CNS."
- Scope: Covers XPro1595 and its peripheral administration for treating Alzheimer's Disease and other Central Nervous System (CNS) diseases.
- Expiration: The patent is set to expire in 2033.
- Ownership: Owned by Xencor, Inc. and exclusively licensed to Inmune Bio, Inc.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) to announce the patent grant, highlighting the protection of its lead candidate, XPro1595, for CNS disorders.
Risks and Contingencies: The filing does not disclose new risks, contingencies, or unusual items beyond the standard context of patent licensing and expiration dates.
Investor Verification Checklist
- Verify the exclusive license agreement terms between Inmune Bio and Xencor, Inc. regarding EP Pat. No. 2,892,547.
- Confirm the specific claims and geographic scope of the granted European patent.
- Review the clinical development status of XPro1595 for Alzheimer's Disease and other CNS indications.
- Check for any pending litigation or oppositions regarding the granted patent.